ge²p² global
governance, ethics, evidence, policy, practice

Public Consultations Watch :: Global Calls for Input/Public Comment/RFIs

Issue 40 :: 01 May 2026

GE2P2 Global is an integrated non-profit foundation and public benefit corporation formed to advance scientific rigor, ethical resilience, and integrity in research and evidence generation – informing responsible governance, policy, and practice.

In the context of this mission, GE2P2 Global monitors public consultations/calls for input/RFIs and similar opportunities across its focus areas of global health, human rights, humanitarian action, education/literacy, heritage, climate/environment, peace, and sustainable development.

Monitoring this span of sectors yields a broad variety of public comment opportunities, even though this modality is not employed in any uniform way across the UN system, multilateral agencies, INGOs, member states or their ministerial/regulatory bodies. As we are still exploring this monitoring approach and broadening the range of calls included, we stress that this is an indicative and not an exhaustive digest.

In parallel, GE2P2 Global is striving to respond to public consultation opportunities where the experience and expertise of members of our growing community of practice suggest that a meaningful contribution can be developed. The GE2P2 Global Foundation also functions as the secretariat for the Global Forum for Research Ethics and Integrity – a global group of individuals from over 30 countries who collaborate on analysis and action, including response to selected public consultations.

We welcome information about calls for public consultation – at global or country level – to help enrich this digest. Equally, individuals and organizations/institutions interested in collaborating on joint responses to any of the opportunities listed below are welcome to contact us [David R Curry, GE2P2 Global Foundation, david.r.curry@ge2p2global.org].

Acknowledgements: We appreciate the support of Foundation Senior Fellow Gerald Schatz, JD for his continuing support in helping identify calls included in this digest, and Associate Fellow Sedem Adiabu, MPH, for her critical role in the secretariat function which supports development of submissions to selected calls.

Digest content is organized in three sections:

We expect to add thematic areas as our digest evolves and becomes more comprehensive.

Calls for Public Consultation: Title/Source/Sorted by Due Date

NEW - **Call for public consultation – Draft Global Action Plan on Skin Diseases as a global health priority (GAP-SKIN)**
20 April 2026 Call for consultation **Deadline: 10 May 2026**

NEW - **Call for proposals: Development, implementation and monitoring of norms and standards for advanced HIV disease**
22 May 2026 **Deadlines: Intention to bid deadline: 15 May 2026,** 23:59 (CEST); Proposal submission deadline: 22 May 2026, 23:59 (CEST)

General Considerations for the Use of New Approach Methodologies in Drug Development; Draft Guidance for Industry; Availability
A Notice by the Food and Drug Administration on 03/19/2026 **Comment period that ends 05/18/2026**

NEW - **Comment Request: Submission of Protocols and Study Reports for Environmental Research Involving Human Subjects (Renewal)**
A Notice by the Environmental Protection Agency on 04/23/2026 **Comment period ends 05/26/2026.**

NEW - **Call for inputs/Human Rights Council resolution 59/15**
Office of the High Commissioner for Human Rights
Issued by OHCHR **Deadline: 01 June 2026**

NEW - **Call for inputs: Report on Reconstruction and Internally Displaced Persons in conflict-affected and mass devastation settings**
Call for input | Special Procedures **Deadline: 15 June 2026**

NEW - **Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments**
A Notice by the Food and Drug Administration on 05/01/2026 **Comment period ends (06/30/2026)**

NEW - **Call for comments - Draft General Comment No. 38 on Article 22 (on the right to freedom of association) of the International Covenant on Civil and Political Rights**
Treaty bodies - Issued by CCPR **Deadline: 30 June 2026**

NEW - **Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry; Availability**
A Notice by the Food and Drug Administration on 04/15/2026 **Comment period ends (07/14/2026)**

FDA Rare Disease Innovation Hub Future Programming; Request for Comments
A Notice by the Food and Drug Administration on 01/30/2026
This document has a **comment period that ends in 328 days. (12/31/2026)**

ISO/AWI 14155 - Biological and clinical evaluation of medical devices

ISO/TC 194 Stage 20.00

Due: Ongoing at national standards bodies level

Contribute a tool - Catalogue of Tools & Metrics for Trustworthy AI

OECD-AI Policy Observatory

Contribute your tools and metrics to our catalogue. No deadline date identified.

This catalogue is a platform where AI practitioners from all over the world can share and compare tools and metrics to help make AI trustworthy, build upon each other's efforts to create global good practices, and speed up the process of implementing the OECD AI Principles. This catalogue can only exist with your contributions and those of AI practitioners from all sectors. You can also share your experience using a tool or metric by submitting a use case.

:: Contribute a tool

:: Share your experience using a tool

A framework for evaluating rapidly developing digital and related technologies: AI, large language models and beyond - International Science Council Discussion Paper: Invitation to Comment

International Science Council [ISC]

No submission deadline date identified.

Public Consultation Calls: Purpose/Objective/Scope/Background Information – Sorted by Thematic Area

Biomedical Research/Regulation/Governance

WMA - Declaration of Taipei Revision Launched *[Ongoing]*

...The Declaration of Taipei tries to achieve a balance between the rights of individuals giving their tissue or data for research and other purposes based on confidentiality and privacy rules while at the same time recognising that health data has become a very powerful tool for increasing knowledge.

In analysing the scenarios that already exist for the use (and misuse) of health data and biobanks, we came to the conclusion that the major risk scenarios may not result from science, but from the commercial, administrative or political use of such data. Limiting our guidelines to research only would have left us blind to the imminent risk of abuse from outside the field of medicine: commercialization, cost-cutting and potential political abuse.

Therefore, in contrast to the Declaration of Helsinki, this policy aims to address any use of health databases and biobanks excluding individual treatment and is not restricted to research. As physicians are the primary custodians of confidential health information, they feel an obligation towards their patients and other persons who entrust them with their data and specimens...

In April 2025, the WMA appointed a workgroup to initiate the revision process of this document. To encourage as much global participation in the revision process as possible, the WMA is collaborating with its members to host a series of regional meetings...

NEW - **Call for public consultation – Draft Global Action Plan on Skin Diseases as a global health priority (GAP-SKIN)**

20 April 2026 Call for consultation **Deadline: 10 May 2026**

On 24 May 2025, the World Health Assembly adopted resolution WHA78.15, recognizing skin diseases as a global public health priority. The resolution requested the Director-General to develop a Global Action Plan for Skin Diseases for consideration by the 80th World Health Assembly in May 2027. In October 2025, the WHO Secretariat conducted a survey among Member States and stakeholders to gather initial inputs on the implications and implementation of the resolution. The findings have contributed to the draft GAP-Skin.

This public consultation aims to gather feedback on the draft document to support its further refinement.

(Draft for review): Global Action Plan on Skin Diseases 2026–2035: Skin Health for All and provide your feedback by clicking on the **Fill in form**.

NEW - **Call for proposals: Development, implementation and monitoring of norms and standards for advanced HIV disease**

22 May 2026 **Deadlines: Intention to bid deadline: 15 May 2026,** 23:59 (CEST); Proposal submission deadline: 22 May 2026, 23:59 (CEST)

WHO's Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections is inviting proposals from qualified institutions to support the development, implementation and monitoring of norms and standards for advanced HIV disease (AHD).

Despite global progress in HIV services, AHD continues to drive high levels of HIV-related morbidity and mortality, particularly in low- and middle-income countries. Strengthening the uptake of WHO

guidelines and improving service delivery for people with AHD remain critical to achieving global HIV targets.
WHO is seeking an institution or consortium to provide technical and programmatic support across guideline development, implementation, monitoring and evaluation, and evidence generation to inform future policy development.

NEW - NIH-Wide Strategic Plan – Public Input

[No due date identified]

NIH seeks community feedback on the next Agency-Wide Strategic Plan. This plan will guide our work over the next five years to fulfill our mission. Input from researchers, other stakeholders, and the general public is essential to ensure transparency in what we do and advance the principles of gold standard science that we all apply to our daily work.

NIH will hold two webinars to gather input from the research community, stakeholders, and the public on the framework that will inform development of the plan:

March 16, 2026, 12:30 to 1:30 PM ET – Registration Link
April 8, 2026, 2:30 to 3:30 PM ET – Registration Link

NEW - Comment Request: Submission of Protocols and Study Reports for Environmental Research Involving Human Subjects (Renewal)

A Notice by the Environmental Protection Agency on 04/23/2026 **Comment period ends 05/26/2026.**

Abstract: The EPA is responsible for the regulation of pesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and the Federal Food, Drug, and Cosmetic Act (FFDCA). Based on this regulation EPA aims to assess the risks of exposure based on studies that may occasionally use humans. Specifically, the EPA regulations at 40 CFR 26 protect subjects of "third-party" human research (*i.e.,* research that is not conducted or supported by the EPA) that may be submitted to EPA in support of pesticide product registration and/or labeling or conducted to provide data for generic exposure databases. In addition to other protections, the regulations require affected entities to submit information to EPA and an institutional review board (IRB) prior to initiating, and to the EPA upon the completion of, certain studies that involve human research participants. The information collection activity consists of activity-driven reporting and recordkeeping requirements for those who intend to conduct research for submission to EPA under the pesticide laws. If such research involves intentional exposure of human subjects, these individuals (respondents) are required to submit study protocols to the EPA and an IRB before such research is initiated so that the scientific design and ethical standards that will be employed during the proposed study may be reviewed and approved. Also, respondents are required to submit information about the ethical conduct of completed research that involved human subjects when such research is submitted to the EPA. As such, the purpose of this document is to estimate the third-party response burden from complying with the requirements in 40 CFR 26.

NEW - General Considerations for the Use of New Approach Methodologies in Drug Development; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 03/19/2026 **Comment period that ends 05/18/2026**

SUMMARY:

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "General Considerations for the Use of New Approach Methodologies in Drug Development." The purpose of this draft guidance is to provide drug developers with a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. Although animal toxicity studies have proved to be a critical method to identify potential

risks to human health, finding ways to improve human relevance while reducing the use of animals by developing reliable NAMs furthers an important Center for Drug Evaluation and Research (CDER) priority to move away from reliance on animal testing. The recommendations in this draft guidance are intended to highlight scientific principles of study design and reporting that can be applied broadly and flexibly in the validation of NAMs used in drug development. This draft guidance is not intended to address specific NAMs and does not address the use of NAMs in drug discovery; rather, it encourages the use of NAMs in regulatory submissions, especially when they improve the predictivity of nonclinical studies for increased safety in clinical trials.

NEW - Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments

A Notice by the Food and Drug Administration on 05/01/2026 **Comment period ends (06/30/2026)**

SUMMARY:

The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect examples about how previous patient-focused drug development (PFDD) meetings have impacted stakeholders' drug development efforts. This includes impacts on community engagement, research priorities, advocacy strategies, medical product development programs, clinical practice, and other areas of interest.

FDA is seeking information that addresses the following:

1. How have PFDD meetings informed patient communities and stakeholder engagement activities?
2. What scientific questions, research initiatives, or identified gaps in the understanding of a disease or condition have resulted from PFDD meetings?
3. In what ways has patient input from PFDD meetings informed medical product development programs or strategies (e.g., endpoint development, clinical trial design, identification of unmet needs, industry partnerships)?
4. How has patient input gathered during PFDD meetings been integrated into or otherwise affected clinical practice?
5. Please describe any other outcomes or effects resulting from PFDD meetings, with examples, that were not addressed in the questions above.

FDA encourages respondents to provide specific examples in their answers where possible.

NEW - Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 04/15/2026 **Comment period ends (07/14/2026)**

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry.” The draft document provides recommendations for next-generation sequencing (NGS)-based methods used in nonclinical studies that will likely be needed to support initiation of clinical trials of investigational human genome editing (GE) products...

This draft guidance is intended for sponsors developing human gene therapy products involving GE technologies. Clinical development programs of human GE products should address both the risks associated with the gene therapy product itself as well as the additional risks associated with GE, including off-target editing and unintended consequences. The recommendations in this draft guidance may guide stakeholders on designing nonclinical studies that uses NGS methods and bioinformatics to evaluate the potential safety risks associated with off-target editing and loss of genome integrity in human GE products submitted in support of Investigational New Drug applications and Biologics License Applications.

The recommendations provided in this draft guidance are in addition to the nonclinical, clinical, and CMC considerations discussed in the "Guidance for Industry: Human Gene Therapy Products Incorporating Human Gene Editing" dated January 2024…

FDA Rare Disease Innovation Hub Future Programming; Request for Comments

A Notice by the Food and Drug Administration on 01/30/2026
This document has a **comment period that ends in 328 days. (12/31/2026)**
SUMMARY:
The Food and Drug Administration (FDA or the Agency) is announcing the following request for comments for a future public workshop series entitled "Rare disease Innovation, Science, and Exploration (RISE) Workshop." The purpose of the public workshops is to focus on challenges that are common to multiple diseases or a class of diseases, and for which evolving science offers innovative solutions. The workshops will primarily focus on cross-cutting or common issues and will not be focused on any specific product under review by the Agency. The Agency further welcomes comments that highlight general rare disease-related issues of potential interest for the FDA Rare Disease Innovation Hub (Hub) to inform its future activities

ISO/AWI 14155 - Biological and clinical evaluation of medical devices

ISO/TC 194 Stage 20.00
Due: Ongoing at level of national standards bodies
Scope
Standardization of the approach to biological and clinical evaluation of medical and dental materials and devices together with standardization of biological test methods applicable to those materials and devices as well as good clinical practice principles to clinical investigations in humans of those devices.
Abstract
This document addresses good clinical practice for the design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the clinical performance or effectiveness and safety of medical devices.
For post-market clinical investigations, the principles set forth in this document are intended to be followed as far as relevant, considering the nature of the clinical investigation (see Annex I).
This document specifies general requirements intended to

— protect the rights, safety and well-being of human subjects,
— ensure the scientific conduct of the clinical investigation and the credibility of the clinical investigation results,
— define the responsibilities of the sponsor and principal investigator, and
— assist sponsors, investigators, ethics committees, regulatory authorities and other bodies involved in the conformity assessment of medical devices.

::::::::::
::::::::::

Human Rights

Call for inputs - Draft General Comment on the Application of the International Covenant on Economic, Social and Cultural Rights in Situations of Armed Conflicts

call for input | Treaty bodies Issued by CESCR **Deadline: 15 May 2026**
Objectives

The main objective of the General Comment is to provide interpretative clarity and authoritative guidance on the application of the ICESCR in situations of armed conflicts. The General Comment will address the entire conflict cycle: structural risk and prevention, active hostilities, occupation or effective control, stabilisation and post-conflict reconstruction. It will clarify how Covenant obligations continue across all phases, and how ESCR protection contributes to conflict prevention, humanitarian action, transitional justice, peacebuilding and sustainable recovery.

Call for inputs - Draft General Comment on the Application of the International Covenant on Economic, Social and Cultural Rights in Situations of Armed Conflicts

UNHCHR - Issued by CESCR **Deadline: 15 May 2026**

Purpose:

To inform the Committee on Economic, Social and Cultural Rights' draft general comment on the Application of the International Covenant on Economic

Objectives

The main objective of the General Comment is to provide interpretative clarity and authoritative guidance on the application of the ICESCR in situations of armed conflicts. The General Comment will address the entire conflict cycle: structural risk and prevention, active hostilities, occupation or effective control, stabilisation and post-conflict reconstruction. It will clarify how Covenant obligations continue across all phases, and how ESCR protection contributes to conflict prevention, humanitarian action, transitional justice, peacebuilding and sustainable recovery.

NEW - Call for inputs/Human Rights Council resolution 59/15

Office of the High Commissioner for Human Rights

Issued by OHCHR **Deadline: 01 June 2026**

Purpose:

To inform the study requested under Human Rights Council resolution 59/15 aimed at assessing the effectiveness of national frameworks for the protection of journalists.

Call for inputs: The impact of trade agreements on women's economic empowerment

Office of the High Commissioner for Human Rights

12 June 2026 **Input/comments must be received by 12 June 2026** .

Objectives

In order to inform the preparation of the report, OHCHR seeks written contributions, comprising replies to the guiding questions below, from United Nations Member States, United Nations entities, including the United Nations Entity for Gender Equality and the Empowerment of Women, the International Labour Organization, the World Trade Organization, the United Nations Children's Fund, the United Nations Conference on Trade and Development and other relevant United Nations agencies, funds and programmes, relevant special procedures of the Human Rights Council, regional organizations and human rights bodies and civil society, including women's and children's rights organizations.

NEW - Call for inputs: Report on Reconstruction and Internally Displaced Persons in conflict-affected and mass devastation settings

Call for input | Special Procedures **Deadline: 15 June 2026**

Issued by Special Rapporteur on the human rights of internally displaced persons

Purpose:

To inform the report of the Special Rapporteur on the human rights of internally displaced persons to be presented to the 81st session of the General Assembly.

Background

Pursuant to Human Rights Council Resolution 59/12, the Special Rapporteur on the human rights of internally displaced persons is preparing a thematic report to be presented to the 81st session of the United Nations General Assembly. The report will examine how reconstruction affects communities and internally displaced persons (IDPs) after conflict or mass-devastation. The report will discuss how reconstruction should be designed and implemented to advance durable solutions, ensure the rights to participation, housing, land and property of internally displaced persons, avoid discrimination and enhance overall human rights protection and sustainable peace.
For the purposes of this report, "mass devastation" refers to contexts in which large-scale destruction of housing, infrastructure, public institutions, essential services, livelihoods and community networks has occurred as a result of armed conflict, occupation, generalized violence, or major disasters, including climate-related events. Such contexts are characterized not only by physical destruction, but also by institutional collapse, environmental contamination (including explosive remnants of war), weakened governance systems, displacement at scale, and profound social and psychological trauma. These conditions create distinct legal, operational and ethical challenges for reconstruction, reconciliation and the pursuit of durable solutions

NEW - **Call for comments - Draft General Comment No. 38 on Article 22 (on the right to freedom of association) of the International Covenant on Civil and Political Rights**

Treaty bodies - Issued by CCPR **Deadline: 30 June 2026**

Purpose:

To provide comments on the draft General Comment No. 38 on Article 22 (right to freedom of association)

Background

At its 144th session, held in July 2025, the Human Rights Committee decided to develop a General Comment on article 22 of the International Covenant on Civil and Political Rights and launched a call for input to inform the preparation of the first draft. At its 145th session, held in March 2026, the Committee completed the first reading of draft General Comment 38. The Committee now invites all interested stakeholders, including Member States, UN entities and specialised agencies, regional human rights mechanisms, unions, national human rights institutions, civil society and academia, to submit comments on the draft ahead of its second reading at the next session.

Draft General Comment No. 38 on Article 22 (right to freedom of association) English |

::::::::::
::::::::::

Emerging/Disruptive Technologies

:: Call for Public Consultation

No new calls identified.

:: Resources, Events

No new resources, events identified.

::::::::::
::::::::::

Biodiversity/Environment/Climate/Disaster Mitigation

:: Call for Public Consultation

:: Resources, Events
No new resources, events identified.

::::::::::
::::::::::

Science Integrity/Evidence to Policy/ Open Science

:: Call for Public Consultation
No new calls identified.

:: Resources, Events
No new resources, events identified.

::::::::::

Heritage/Cultural Assets

:: Call for Public Consultation
No new calls identified.

:: Resources, Events
No new resources, events identified.

::::::::::
::::::::::

Governance, Peace, Trade, Global Finance

:: Call for Public Consultation
No new calls identified.

:: Resources, Events
No new resources, events identified.

::::::::::
::::::::::

Selected Final, Published Guidances, Frameworks, Regulations, Meetings Employing Calls for Public Consultation

E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports; International Council for Harmonisation

A Notice by the Food and Drug Administration on 03/04/2026 **FINAL GUIDANCE**

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of a **final guidance** for industry entitled "E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports." The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

(ICH). The guidance updates the 2003 guidance titled "E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting," by clarifying the use of new or increasingly used data sources (*e.g.,* social media, market research programs, patient support programs). This final guidance clarifies the use of new postapproval safety sources and update terminology and standards for postapproval adverse event reporting. The guidance replaces the draft guidance "E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports" issued on March 14, 2024, and the final guidance issued September 15, 2003.

M14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines; International Council for Harmonisation

A Notice by the Food and Drug Administration on 03/04/2026 **FINAL GUIDANCE**

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines." The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance outlines general principles on planning, designing, analyzing, and reporting non-interventional studies that utilize real-world data for safety assessment of medicines (*i.e.,* drugs, vaccines, and other biological products). The recommendations in this guidance, while focused on safety, are applicable to non-interventional studies assessing effectiveness and are aligned and complementary with the FDA's other guidances on the generation real world evidence. The guidance includes recommendations and high-level best practices for the conduct of these studies, including articulating the research question, selecting appropriate data sources, defining key variables, addressing potential biases and confounding, conducting analyses, reporting, and submission.

::::::::::
::::::::::

Selected Peer-reviewed Journal Literature/Gray Lit Integrating Public Consultation

OECD Guidelines for Citizen Participation Processes

Paris: OECD Publishing. 2022
https://www.oecd-ilibrary.org/governance/oecd-guidelines-for-citizen-participation-processes_f765caf6-en [Accessed 10 Nov 2023]

The *OECD Guidelines for Citizen Participation Processes* are intended for any public official or public institution interested in carrying out a citizen participation process. The guidelines describe ten steps for designing, planning, implementing and evaluating a citizen participation process, and discuss eight different methods for involving citizens: information and data, open meetings, public consultations, open innovation, citizen science, civic monitoring, participatory budgeting and representative deliberative processes. The guidelines are illustrated with examples as well as practical guidance built on evidence gathered by the OECD. Finally, nine guiding principles are presented to help ensure the quality of these processes.

::::::::::
::::::::::

Selected Resources for Public Consultation Notices, Calls, Processes

UNHCHR UN High Commissioner for Human Rights – Calls for Input
https://www.ohchr.org/en/calls-for-input-listing

UNESCO - Consultations
https://www.unesco.org/en/search?category=UNESCO&text=consultation&category=UNESCO&sort_by=unesco_date#toggle-facets

WHO – Public Consultations
https://www.who.int/home/search?indexCatalogue=genericsearchindex1&searchQuery=public%20consultation&wordsMode=AnyWord

OECD - Consultations and calls for contributions
https://www.oecd.org/about/civil-society/consultations-and-calls-for-contributions.htm

IFAD Public Consultations
https://webapps.ifad.org/members/executive-board-public-consultation

European Medicines Agency's (EMA) open public consultations
https://www.ema.europa.eu/en/news-events/open-consultations

U.S. Federal Register – "Public Comment" or RFI
https://www.federalregister.gov/documents/search?conditions%5Bpublication_date%5D%5Bgte%5D=09%2F13%2F2023&conditions%5Bterm%5D=%22public+comment%22+or+RFI#

U.S. HHS – Open Requests for Comments
https://www.hhs.gov/ohrp/regulations-and-policy/requests-for-comments/index.html

* * * *